Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients

Bone Marrow Transplantation

Volumn 17, Issue 4, 1996, Pages 589-593

  Canpolat, C ^a   Culbert, S ^a   Gardner, M ^a   Whimbey, E ^a   Tarrand, J ^a   Chan, K W ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic; Bone marrow transplantation; Children; Cytomegalovirus infection; Ganciclovir

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOGLOBULIN;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CHEMOPROPHYLAXIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOCYTOPENIA; URINALYSIS; VIREMIA;

ADOLESCENT; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; INCIDENCE; INFANT; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE DEPLETION; MALE; NEUTROPENIA; PNEUMONIA, VIRAL; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIREMIA; VIRUS ACTIVATION;

EID: 0029959973     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
2. Miller W, Flynn P, McCullough J et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-versus-host disease. Blood 1986; 67: 1162-1167.
3. Wingard JR, Mellits ED, Sostrin MB et al. Interstitial pneumonitis after allogeneic bone marrow transplantation: nine-year experience at a single institution. Medicine 1988; 57: 175-186.
4. Weiner RS, Bortin MM, Gale RP et al. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med 1986; 104: 168-175.
5. Locatelli F, Percivalle E, Comoli P et al. Human cytomegalovirus infection in pediatric patients given allogeneic bone marrow transplantation: role of early antiviral treatment of HCMV antigenemia on patient's outcome. Br J Haematol 1994; 88: 64-71.
6. Miller WJ, McCullough J, Balfour HH Jr et al. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 1991; 7: 227-234.
7. Winston DJ, Ho WG, Lin H et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12-18.
8. Schmidt GM, Horak DA, Niland JC et al. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplantation. New Engl J Med 1991; 324: 1005-1011.
9. Goodnch JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
10. Goodrich JM, Bowden RA, Fisher L et al. Prevention of cytomegalovirus disease after allogeneic marrow transplant by ganciclovir prophylaxis. Ann Intern Med 1993; 118: 173-178.
11. Cleaves CA, Smith TF, Shuster EA et al. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984; 19: 917-919.
12. Inston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of placebo-controlled double blind trial. Ann Intern Med 1993; 118: 179-184.
13. Onbluetzingsloewen A, Bordigoni P, Witz F et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 197-202.
14. Rzepiorka D, Ippoliti C, Panina J et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 1994; 13: 461-464.
15. Achado CM, Dulley FL, Ostronoff M et al. Low-dose ganciclovir prophylaxis to prevent cytomegalovirus infection after bone marrow transplantation. 8th International Symposium of Infections in the Immunocompromised Host, Davos, Switzerland, 1994 (abstr. 67).
16. Enright H, Haake R, Weisdorf D et al. Cytomegalovirus pneumonia after bone marrow transplantation: risk factors and response to therapy. Transplantation 1993; 55: 1339-1346.
17. Bacigalupo A, Van Lint MT, Tedone E et al. Early treatment of CMV infection in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant 1994; 13: 753-758.
18. Webster A, Blizzard B, Pilloy D et al. Value of routine surveillance culture for detection fo CMV pneumonitis following bone marrow transplantation. Bone Marrow Transplant. 1993; 12: 477-481.
19. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162: 373-380
20. Roberts WD, Weinberg KI, Kohn DB et al. Granulocyte recovery in pediatric marrow transplant recipients treated with ganciclovir for cytomegalovirus infection. Am J Pediatr Hematol Oncol 1993; 15: 320-323.
21. Faulds D, Heel RC. Ganciclovir, a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infection. Drugs 1990; 39: 597-638.
22. Boeckh M, Myerson D, Bowden RA. Early detection and treatment of cytomegalovirus infections in marrow transplant patients: methological aspects and implications for therapeutic interventions. Bone Marrow Transplant 1994; 14 (Suppl. 4): 566-570.
23. Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993; 56: 330-334.